Open an account

Synlogic

SYBX · OTC

$1.08+$0.01 (+0.93%)TodayMarket closed ·
Prev close $1.07

About SYBX

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. The company is headquartered in Winchester, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2015-09-30. The firm is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The firm's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The firm designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.

Employees
1
Headquarters
Winchester, Massachusetts
Listed
Sep 30, 2015
Sector
Health Care
Industry
Biotechnology
Website
synlogictx.com

SYBX key statistics

Market cap
13.23M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
30.13K
Volume
639
Open price
$1.03
High today
$1.08
Low today
$0.975
52 Week high
$1.87
52 Week low
$0.56

Synlogic (SYBX) at a glance

As of Oct 20, 2026, Synlogic (SYBX) shares are priced at $1.08, giving the company a market cap of 13.23M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.975 and $1.08. The current price is 10.8% above the day's low and 0.0% below its high.

Volume so far is 639 shares, below the average of 30.13K shares a day.

Over the past year Synlogic has ranged from $0.56 to $1.87, and now sits 40% of the way up that range.

Synlogic met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY24 it reported -$0.06 per share against an estimate of -$0.102.

SYBX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 48.0% on average.

  1. Q1 FY23: reported -$3.45 per share against an estimate of -$3.56
  2. Q2 FY23: reported -$3.15 per share against an estimate of -$3.62
  3. Q3 FY23: reported -$2.57 per share against an estimate of -$2.72
  4. Q4 FY23: reported -$1.71 per share against an estimate of -$0.986
  5. Q1 FY24: reported -$2.60 per share against an estimate of -$0.8364
  6. Q2 FY24: reported $0.16 per share against an estimate of -$0.5202
  7. Q3 FY24: reported -$0.01 per share against an estimate of -$0.1836
  8. Q4 FY24: reported -$0.06 per share against an estimate of -$0.102

SYBX news

  • Press releaseBusiness Wire

    SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders

  • Press releaseBusiness Wire

    Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

  • Avi Kapoor

    Crude Oil Gains 2%; D.R. Horton Earnings Top Views

  • Avi Kapoor

    Dow Falls Over 500 Points; 3M Posts Upbeat Earnings

  • Press releaseBusiness Wire

    The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Synlogic

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.